@article {10.3844/ajbbsp.2022.386.393, article_type = {journal}, title = {Evaluation of Anti-Inflammatory Potential of Turmimax® an in vivo and in vitro Study}, author = {H M., Firoz Hussain and S., Nanjundaiah and Thimmegowda, Sadashiva Channangihalli and Benny, Neethumol and Y., Rashmi}, volume = {18}, number = {4}, year = {2022}, month = {Nov}, pages = {386-393}, doi = {10.3844/ajbbsp.2022.386.393}, url = {https://thescipub.com/abstract/ajbbsp.2022.386.393}, abstract = {The main objective of this study was to investigate the in vivo and in vitro anti-inflammatory effects of the Turmimax® bio-enhanced turmeric formulation. By comparing the relative fluorescence intensities of the interleukins IL-8 (Interleukin-8) and IL-12 (Interleukin-12) cytokines in stimulated murine Raw 264.7 macrophages, Turmimax® was evaluated for its anti-inflammatory in vitro efficacy. Turmimax® was administered orally in two doses, 100 and 200 mg/kg, to assess its in vivo anti-inflammatory potential in ear edema induced by croton oil in mice and paw edema induced by histamine in albino rats. Diclofenac sodium 10 mg/kg p.o. is the standard drug. The results demonstrated that Turmimax® significantly and dose-dependently decreased the production of the inflammatory mediator’s interleukin-8 and IL-12. According to the current investigation results, Turmimax® has shown strong anti-inflammatory effects.}, journal = {American Journal of Biochemistry and Biotechnology}, publisher = {Science Publications} }